Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects - Morcos, Peter N.; Yu, Li; Bogman, Katrijn; Sato, Mika; Katsuki, Hisakazu; Kawashima, Kosuke; Moore, David J; Whayman, Matt; Nieforth, Keith; Heinig, Katja; Guerini, Elena; Muri, Dieter; et al. (Xenobiotica, 2017)
Keywords: Adult; Biological Availability; Carbazoles - metabolism; Carbazoles - pharmacokinetics; Cross-Over Studies; Healthy Volunteers; Humans; Intravenous; Male; metabolites; microtracer; Middle Aged; pharmacokinetics; Piperidines - metabolism; Piperidines - pharmacokinetics; Protein Kinase Inhibitors - metabolism; Protein Kinase Inhibitors - pharmacokinetics; radiolabelled alectinib; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Tissue Distribution; radiolabelled alectinib; pharmacokinetics; Intravenous; metabolites; microtracer